Bedford, Massachusetts, United States, August 2025 – Sara Den Besten has taken on the role of Chief People Officer at Stoke Therapeutics, where she will lead the company’s people strategy and oversee initiatives that enhance organizational culture, talent development, and employee engagement in alignment with Stoke’s mission to advance RNA-based medicines.
Prior to joining Stoke Therapeutics, Sara served as Managing Partner at Den Besten Group for over a year, providing strategic HR consulting, culture change initiatives, and leadership development solutions. She partnered with CEOs and senior teams to design and implement people strategies, drive organizational transformation, and deliver high-impact coaching and capacity-building programs.
Before that, Sara spent six years at Generation Bio, holding multiple leadership roles, including Chief Culture and Engagement Officer, Chief People Officer, and SVP, Head of Human Resources. During her tenure, she played a pivotal role in shaping company culture, advancing employee engagement, and integrating strategic people practices into the business framework.
Earlier, Sara led her own consulting practice as Managing Partner of Den Besten Group for six years, specializing in leadership development, organizational design, change management, and executive coaching. She also worked extensively with senior executives to build leadership capacity and foster sustainable performance.
Sara dedicated nearly 11 years to Genzyme, part of Sanofi, in roles including Director, Leadership and Organization Development, Consultant, Leadership and Organization Development, and Director, Patient Advocacy. She was instrumental in implementing global leadership models, designing talent and leadership development programs, and strengthening connections between employees and patient communities. Her earlier career includes roles at The Lewis Clinic and School, Princeton University, and Brigham and Women’s Hospital.
About Stoke Therapeutics
Stoke Therapeutics (Nasdaq: STOK) is a biotechnology company pioneering RNA-based medicines to restore protein expression through its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach. The company’s lead medicine, zorevunersen, is in Phase 3 development for Dravet syndrome and has shown potential for disease modification. Stoke’s initial focus is on diseases of the central nervous system and the eye caused by haploinsufficiency, with broader applications across multiple organ systems.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
